secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-204125
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics signs manufacturing deal with Emergent for SAB-142; $36M minimum spend post-FDA approval
--------------------------------------------------------------------------------

- Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.
- Term runs 5 years from FDA approval; minimum aggregate spend of $36 million after approval.
- Emergent has exclusive manufacturing rights during term; SAB may seek alternative source in limited cases.
- Commercial batch price to be set in amendment within 18 months of anticipated commercial sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/0001193125-26-204125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/sabs-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer